Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cheung

Showing results (291-300 of 298) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 298 results.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Journal of Medicinal Chemistry|April 11, 2020
Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 DegradersBenjamin R Bellenie, Kwai-Ming J Cheung, Ana Varela, et al.
Scientific Reports|November 4, 2022
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assaysOlivier A Pierrat, Manjuan Liu, Gavin W Collie, et al.
Journal of Medicinal Chemistry|June 2, 2022
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>Rosemary Huckvale, Alice C Harnden, Kwai-Ming J Cheung, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Conservation Physiology|July 21, 2025
Co-production and conservation physiology: outcomes, challenges and opportunities arising from reflections on diverse co-produced projectsSteven J Cooke, Nolan N Bett, Scott G Hinch, et al.
Immunity|May 24, 2024
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell deathJonathan Mannion, Valentina Gifford, Benjamin Bellenie, et al.
G3 (Bethesda, Md.)|November 7, 2019
Expression-Based Cell Lineage Analysis in <i>Drosophila</i> Through a Course-Based Research Experience for Early UndergraduatesJohn M Olson, Cory J Evans, Kathy T Ngo, et al.
Pageof 30

Showing results (291-300 of 298) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 298 results.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Journal of Medicinal Chemistry|April 11, 2020
Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 DegradersBenjamin R Bellenie, Kwai-Ming J Cheung, Ana Varela, et al.
Scientific Reports|November 4, 2022
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assaysOlivier A Pierrat, Manjuan Liu, Gavin W Collie, et al.
Journal of Medicinal Chemistry|June 2, 2022
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>Rosemary Huckvale, Alice C Harnden, Kwai-Ming J Cheung, et al.
Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.
Conservation Physiology|July 21, 2025
Co-production and conservation physiology: outcomes, challenges and opportunities arising from reflections on diverse co-produced projectsSteven J Cooke, Nolan N Bett, Scott G Hinch, et al.
Immunity|May 24, 2024
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell deathJonathan Mannion, Valentina Gifford, Benjamin Bellenie, et al.
G3 (Bethesda, Md.)|November 7, 2019
Expression-Based Cell Lineage Analysis in <i>Drosophila</i> Through a Course-Based Research Experience for Early UndergraduatesJohn M Olson, Cory J Evans, Kathy T Ngo, et al.
Pageof 30